Publications

Sponsor kills ExoFlo perianal fistula trial after enrolling five patients

Author: Andrew Jonathan Hillman (ORCID 0009-0001-5396-321X)
Published: , Zenodo. Also published in The Hillman Letter.
DOI: 10.5281/zenodo.23352288 (all versions); this version 10.5281/zenodo.23352289
License: CC BY 4.0

The sponsor terminated its Phase 1/2 ExoFlo trial in Crohn's-associated perianal fistula (NCT05836883) in August 2026 after enrolling five subjects. The stated reason was enrollment challenges, not a safety signal or failed endpoint. It followed the sponsor's 2025 terminations in ulcerative colitis and Crohn's trials. ExoFlo is investigational, and no exosome product is FDA approved.

Exosome, stem cell and extracellular vesicle products discussed here are not approved by the FDA for any indication. This essay describes regulatory and public records. It does not describe an available treatment, and it is not legal advice.

Abstract

Reports the August 2026 termination of a Phase 1/2 trial of an investigational bone marrow MSC-derived extracellular vesicle product in Crohn's-associated perianal fistula (NCT05836883) after five subjects enrolled. Notes the stated reason was enrollment challenges and places it alongside earlier terminations by the same sponsor.

Indexed in OpenAlex under author A5139488776.

Why was the ExoFlo perianal fistula trial terminated?

Is the sponsor still studying perianal fistula?

What is the status of the ExoFlo ARDS trial?

Is ExoFlo FDA approved?

Why do cell and EV therapy trials fail to enroll?

Sources

All publications · Andrew J. Hillman · Andrew Hillman, Dallas on LinkedIn · Book a meeting